ARCHIVES

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Bunn Says ASCO Is “Strong, Diverse, Respected, Growing”

June 6, 2003

GAO Criticizes Eppley, NCI For ‘Deficiencies’ In Review, Monitoring, Management of Contract

February 24, 1978

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

July 13, 2007

Professional Societes; ASCO’s Strength Is In Its Diversify, Lichtor Says

May 21, 1999

New Mammography Guidelines Cut Uses By Women Under 50 t 25%

July 29, 1977

NCI Faced Pressure From Congress, HHS, White On Mammography Statement

April 11, 1997